Last reviewed · How we verify

NSAID-Induced Gastric Ulcer — Treatment Landscape & Competitive Intelligence

NSAID-Induced Gastric Ulcer (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating NSAID-Induced Gastric Ulcer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Prevacid lansoprazole Generic (originally Takeda) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase 1995-05-10
Prevacid Prevacid Vanderbilt University Medical Center ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Takeda) · 1 drug in NSAID-Induced Gastric Ulcer
  2. Vanderbilt University Medical Center · 1 drug in NSAID-Induced Gastric Ulcer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in NSAID-Induced Gastric Ulcer:

Cite this brief

Drug Landscape (2026). NSAID-Induced Gastric Ulcer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nsaid-induced-gastric-ulcer. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing